PremiumThe FlyRevolution Medicines price target raised to $75 from $70 at Oppenheimer Revolution Medicines: Strategic Advancements in NSCLC Treatment Drive Buy Rating Revolution Medicines’ Promising RAS+ NSCLC Market Position and Drug Efficacy Justify Buy Rating PremiumRatingsPositive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib Revolution Medicines shares up 6% after presenting initial RMC-9805 study data Promising Phase 1 Results for Revolution Medicines’ Zoldonrasib in NSCLC Support Buy Rating PremiumCompany AnnouncementsRevolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs Revolution Medicines Reports 2024 Financial Results and Progress Revolution Medicines reports Q4 EPS ($1.12), consensus (96c)